Relay Therapeutics, Inc. develops clinical-stage small molecule precision medicines for cancer and genetic disease. The company uses its Dynamo® platform, which combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed.
Recurring RLAY news centers on zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor studied in HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies. Company updates also cover pipeline programs for NRAS-driven solid tumors and Fabry disease, clinical and regulatory data presentations, operating results, capital-structure matters, license or collaboration agreements, and governance developments.
Relay Therapeutics (Nasdaq: RLAY) reported a third-quarter 2026 net loss of $81.7 million and updated its breast cancer and vascular anomalies programs. The loss widened from $74.1 million a year earlier, while loss per share narrowed to $0.37 from $0.43. Cash, cash equivalents and investments totaled $848.6 million, down from $910.9 million at June 30.
The company expects funding into 2029, estimates Phase 3 ReDiscover-2 enrollment completion in mid-2027, and plans a frontline breast cancer Phase 3 trial in early 2027. Updated Phase 1/2 ReInspire vascular anomalies data and a regulatory update are planned for December 14. A newly announced mutant-selective TIE2 inhibitor program is in late-stage preclinical development. The FDA granted full approval to LYRFIGTU (lirafugratinib), licensed worldwide to Elevar Therapeutics. Shannon Campbell joined as head of commercial.
Relay Therapeutics (Nasdaq: RLAY) announced that management will participate in fireside chats at three investor conferences in November 2026.
The schedule includes Guggenheim on November 10 at 4:30 p.m. ET, UBS on November 17 at 3:00 a.m. ET, and Jefferies on November 18 at 10:30 a.m. ET. Live webcasts will be accessible through the company’s website, with archived replays available for up to 30 days following each event.
Relay Therapeutics (RLAY) will announce third quarter 2026 financial results and corporate highlights on November 4, 2026. The announcement is scheduled for after U.S. financial markets close that Wednesday.
Relay Therapeutics (Nasdaq: RLAY) announced that management will participate in two September 2026 investor fireside chats: the Wells Fargo Healthcare Conference on September 8, 2026 at 1:30 p.m. ET and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026 at 9:15 a.m. ET. Live webcasts and 30-day replays will be available via the company’s investor relations website.
Relay Therapeutics (Nasdaq: RLAY) reported Q2 2026 results highlighted by progress for lead PI3Kα inhibitor zovegalisib and a strengthened balance sheet. The company selected zovegalisib plus atirmociclib as the go-forward triplet regimen for first-line (1L) HR+/HER2-, PI3Kα-mutated breast cancer and plans a Phase 3 1L trial in endocrine-sensitive patients in early 2027, subject to regulatory feedback. In heavily pre-treated, CDK4/6-experienced median third-line breast cancer, the triplet showed a 44% objective response rate at unoptimized doses. Initial Phase 1/2 ReInspire data in PIK3CA-driven vascular anomalies showed 60% volumetric responses at 12 weeks and symptomatic improvement in nearly all patients, with a safety profile supporting potential chronic use. Relay continued the Phase 3 ReDiscover-2 2L breast cancer trial and Phase 1/2 RLY-8161 trial in NRAS-mutant tumors. Q2 cash, cash equivalents and investments were $910.9 million, boosted by approximately $316 million gross proceeds from a May 2026 follow-on offering, and the company expects runway into 2029. Revenue was $0.4 million, R&D expenses $76.5 million, G&A expenses $14.7 million and net loss $83.7 million ($0.41 per share).
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage small molecule precision medicine company focused on therapies for cancer and genetic diseases, plans to report its second quarter 2026 financial results and corporate highlights after U.S. market close on Thursday, August 6, 2026.
The announcement outlines the timing of the upcoming financial disclosure and related corporate update, allowing investors and analysts to prepare for Relay Therapeutics’ next scheduled earnings communication.
Relay Therapeutics (Nasdaq: RLAY) announced that management will participate in two investor fireside chats in June 2026.
Events include the 2026 Jefferies Global Healthcare Conference on June 3 at 12:45 p.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 at 8:40 a.m. ET. Both will be webcast live, with replays available for 30 days.
Relay Therapeutics (Nasdaq: RLAY) priced an underwritten public offering of 22,916,667 common shares at $12.00 per share. Underwriters have a 30-day option to buy up to 3,437,500 additional shares.
Gross proceeds are expected to be about $275 million, before fees, with closing expected on or about May 22, 2026, subject to customary conditions.
Relay Therapeutics (Nasdaq: RLAY) has launched an underwritten public offering of $175 million of common stock. The company plans to grant underwriters a 30-day option to buy up to an additional 15% of the shares.
All shares are to be sold by Relay Therapeutics under an effective Form S-3ASR shelf registration. Jefferies, TD Cowen, Goldman Sachs and Guggenheim Securities are joint bookrunners, with Raymond James as lead manager. The deal’s timing, size and terms remain subject to market conditions.
Relay Therapeutics (Nasdaq: RLAY) reported initial Phase 2 ReInspire data for zovegalisib in PIK3CA-driven vascular anomalies. Among 20 response-evaluable adults/adolescents, 60% showed volumetric lesion response at 12 weeks, rising to 65% after data cut-off, with 89% investigator- and 79% patient-reported clinical improvement and an interim safety profile supporting chronic dosing at optimized regimens.